NuView Life Sciences Announces the Appointments of Dr. Stanley J. Pappelbaum and A.J. Boechler to Board of Directors
PARK CITY, Utah, Jan. 3, 2024 /PRNewswire/ -- NuView Life Sciences, Inc. ("NuView", the "company"), a radiopharmaceutical company seeking to enhance the global oncology market with its novel platform (NV-VPAC1™) capable of detecting and precisely targeting G protein-coupled receptors for cancer, announced the appointments of Dr. Stanley J. Pappelbaum and A.J. Boechler to its board of directors. Their combined experience and expertise developing, commercializing, and scaling therapeutics that span the product lifecycle adds further depth to NuView's leadership team as the Company advances its NV-VPAC1™ theranostic technology towards key clinical and commercialization milestones in 2024. NuView is leveraging its NV-VPAC1™ platform to advance a pipeline of precision in vitro laboratory diagnostics tests and in vivo cancer diagnostics and therapy delivery systems targeting multiple high-need, large-market indications, including prostate and bladder cancer.
- Boechler to its board of directors.
- "On behalf of the Board, I am pleased to welcome Stan and A.J.
- and look forward to benefitting from their knowledge and expertise," said Paul Crowe, Chairman and Chief Executive Officer of NuView.
- Boechler joins the NuView board offering more than 30 years of executive leadership experience at the General Electric Company.